Furegrelate Sodium (1-5 mg/kg; po) prevents blockage of the coronary artery[1].
Furegrelate Sodium (0.1-5 mg/kg; i.v.) prevents the blockage of stenosed coronary arteries caused platelet aggregation[1].
Furegrelate Sodium blunts the development of hypoxia-induced pulmonary arterial hypertension (PAH) in an established neonatal piglet model primarily by preserving the structural integrity of the pulmonary vasculature[2].
Furegrelate has a long half-life compared to several other drugs used to treat PAH, including nitric oxide and prostagcyclin analogues; And Furegrelate is highly specific to the target enzyme[2].
| Animal Model: | Mongrel dogs (19-30 kg)[1] |
| Dosage: | 1-5 mg/kg |
| Administration: | Oral (via a gastric tube) |
| Result: | Prevented blockage of the coronary artery. |
